The Effects of the ManageHF4Life Mobile App on Patients With Chronic Heart Failure: Randomized Controlled Trial
Overview
Medical Informatics
Affiliations
Background: The successful management of heart failure (HF) involves guideline-based medical therapy as well as self-management behavior. As a result, the management of HF is moving toward a proactive real-time technological model of assisting patients with monitoring and self-management.
Objective: The aim of this paper was to evaluate the efficacy of enhanced self-management via a mobile app intervention on health-related quality of life, self-management, and HF readmissions.
Methods: A single-center randomized controlled trial was performed. Participants older than 45 years and admitted for acute decompensated HF or recently discharged in the past 4 weeks were included. The intervention group ("app group") used a mobile app, and the intervention prompted daily self-monitoring and promoted self-management. The control group ("no-app group") received usual care. The primary outcome was the change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 6 and 12 weeks. Secondary outcomes were the Self-Care Heart Failure Index (SCHFI) questionnaire score and recurrent HF admissions.
Results: A total of 83 participants were enrolled and completed all baseline assessments. Baseline characteristics were similar between the groups except for the prevalence of ischemic HF. The app group had a reduced MLHFQ at 6 weeks (mean 37.5, SD 3.5 vs mean 48.2, SD 3.7; P=.04) but not at 12 weeks (mean 44.2, SD 4 vs mean 45.9, SD 4; P=.78), compared to the no-app group. There was no effect of the app on the SCHFI at 6 or 12 weeks. The time to first HF readmission was not statistically different between the app group and the no-app group (app group 11/42, 26% vs no-app group 12/41, 29%; hazard ratio 0.89, 95% CI 0.39-2.02; P=.78) over 12 weeks.
Conclusions: The adaptive mobile app intervention, which focused on promoting self-monitoring and self-management, improved the MLHFQ at 6 weeks but did not sustain its effects at 12 weeks. No effect was seen on HF self-management measured by self-report. Further research is needed to enhance engagement in the app for a longer period and to determine if the app can reduce HF readmissions in a larger study.
Trial Registration: ClinicalTrials.gov NCT03149510; https://clinicaltrials.gov/ct2/show/NCT03149510.
Kitsiou S, Gerber B, Buchholz S, Kansal M, Sun J, Pressler S J Med Internet Res. 2025; 27:e55586.
PMID: 39813671 PMC: 11780297. DOI: 10.2196/55586.
Platform-Based Patient-Clinician Digital Health Interventions for Care Transitions: Scoping Review.
Backman C, Papp R, Tonjock Kolle A, Papp S, Visintini S, Ferreira de Mello A J Med Internet Res. 2025; 26:e55753.
PMID: 39753212 PMC: 11729789. DOI: 10.2196/55753.
Wang L, Zhao Y, Han L, Zhang H, Chen H, Liu A JAMA Netw Open. 2024; 7(12):e2453976.
PMID: 39705029 PMC: 11662253. DOI: 10.1001/jamanetworkopen.2024.53976.
Kim D, Eltahir A, Ngo S, Rodriguez F Curr Atheroscler Rep. 2024; 27(1):9.
PMID: 39576395 DOI: 10.1007/s11883-024-01249-9.
Huang Y, Li S, Lu X, Chen W, Zhang Y Healthcare (Basel). 2024; 12(21).
PMID: 39517362 PMC: 11544912. DOI: 10.3390/healthcare12212151.